• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceREVANESSE ULTRA
Generic Nameimplant, dermal, for aesthetic use
Applicant
PROLLENIUM MEDICAL TECHNOLOGIES INC.
138 industrial parkway north
aurora L4G 4
PMA NumberP160042
Date Received09/22/2016
Decision Date08/04/2017
Product Code LMH 
Docket Number 17M-4711
Notice Date 08/07/2017
Advisory Committee General & Plastic Surgery
Clinical Trials NCT02984878
Expedited Review Granted? No
Combination Product No
Recalls CDRH Recalls
Approval Order Statement 
Approval for the Revanesse Ultra. The device is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Labeling Part 2
Supplements:  S009 S007 S010 S011 S012 S004 S003 S001 
-
-